---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-191553"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:35:59.659139+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M

## Summary
- Record net sales $150.6M (+41% YoY, +39% constant currency).
- U.S. Glaucoma net sales $93.5M (+58% YoY); Glaucoma total $129.3M (+47% YoY).
- GAAP net loss ($0.34)/share; non-GAAP net loss ($0.18)/share; operating loss narrowed YoY.
- FY2026 net sales guidance raised to $620-635M from prior $600-620M.
- Cash $280.5M, no debt; GAAP gross margin ~78%, non-GAAP ~84%.

## SEC filing metadata
- accession: 0001193125-26-191553
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/0001193125-26-191553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/gkos-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-191553
- JSON: https://secwatch.observer/filing/0001193125-26-191553.json
- Plain text: https://secwatch.observer/filing/0001193125-26-191553.txt

## Key facts
- Earnings Releases
  GLAUKOS Corp reported the first quarter ended March 31, 2026 results: revenue $150.6 million, net income $19.8 million, EPS ($0.34) per diluted share. Guidance raised.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $150.6 million
  - Net income: $19.8 million
  - EPS: ($0.34) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: • Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. • Glaucoma record net sales of $129.3 million in Q1 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1192448/000119312526191553/0001193125-26-191553-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.